We found that the expression of the cancer stem cell marker CD133 is associated with reduced cell proliferation and DNA repair, yet heightened inflammation, and is linked to a more favorable outcomes after NAC and improved survival among ER-positive/HER2-negative BC patients. Here, ERBB2 is linked to cancer.